

1 **Running title:** defensin with angiotensin converting enzyme inhibitory activity

2

3 **Sweet potato storage root defensin and their tryptic hydrolysates**
4 **exhibited angiotensin converting enzyme inhibitory activity *in vitro***

5

6 Guan-Jhong Huang^{1,*,#}, Te-Ling Lu^{2,#}, Chuan-Sung Chiu^{1,3}, Hsien-Jung Chen⁴, Chieh-Hsi
7 Wu², Ying-Chin Lin⁵, Wen-Tsong Hsieh⁶, Jung-Chun Liao², Ming-Jyh Sheu², and
8 Yaw-Huei Lin^{7*}

9

10 ¹School of Chinese Pharmaceutical Sciences and Chinese medicine resources, China
11 Medical University, Taichung 404, Taiwan;

12 ² School of Pharmacy, China Medical University, Taichung 404, Taiwan;

13 ³ Nursing Department, Hsin Sheng College of Medical Care and Management, Taoyuan
14 325, Taiwan;

15 ⁴Department of Biological Sciences, National Sun Yat-Sen University, Kaohsiung 804,
16 Taiwan;

17 ⁵ Nursing and management, Jen-Teh Junior college of Medicine, Taiwan;

18 ⁶ Department of Pharmacology, China Medical University, Taichung 404, Taiwan;

19 ⁷ Institute of Plant and Microbial Biology, Academia Sinica, Nankang, Taipei 115, Taiwan;

20

21 ***Corresponding author:**

22 Dr. Yaw-Huei Lin

23 Institute of Plant and Microbial Biology, Academia Sinica, Nankang, Taipei 11529,
24 Taiwan, ROC;

25 FAX: 886 (2) 2782-7954; TEL: 886 (2) 2787-1172

26 E-mail: boyhlin@gate.sinica.edu.tw

27

28 Dr. Guan-Jhong Huang

29 School of Chinese Pharmaceutical Sciences and Chinese medicine resources, China
30 Medical University, Taichung 404, Taiwan;

31 Tel.: +886 4 2205 3366 ext 5508; Fax: +886 4 2208 3362.

32 E-mail address: gjhuang@mail.cmu.edu.tw

33 [#] These two authors contributed equally to this work.

34

MS NO. 3192

35 **Abstract:**

36 Sweet potato defensin (SPD1) overproduced in *E. coli* (M15) was purified by
37 Ni²⁺-chelate affinity chromatography. The molecular mass of SPD1 is about 8,600 Da
38 determined by SDS (sodium dodecyl sulfate)-PAGE (polyacrylamide gel electrophoresis).
39 Our previously paper showed that SPD1 had antimicrobial, dehydroascorbate reductase
40 and monodehydroascorbate reductase activities. The activity of SPD1 to inhibit
41 angiotensin converting enzyme (ACE) was shown by using N-[3-(2-furyl)
42 acryloyl]-Phe-Gly-Gly (FAPGG) as substrate in a dose-dependent manner (27.56 ~ 52.58
43 % inhibition). The 50% inhibition (IC₅₀) of ACE activity required 190.47 µg/mL SPD1
44 while that of Captopril was 10 nM (868 ng/mL). The use of thin layer chromatography
45 (TLC) also showed SPD1 as an ACE inhibitor. SPD1 acted as a mixed type inhibitor
46 against ACE using FAPGG as a substrate. When 200 µg/mL SPD1 (10 µg) were added,
47 V_{max} and K_m were, respectively, 0.01 ΔA/min and 0.69 mM; while without SPD1 they
48 were 0.03 ΔA/min and 0.42 mM. Trypsin was used for SPD1 hydrolysis for different
49 times. It was found that the ACE inhibitory activity increased from 52.47 % to about
50 74.38 % after 24 h hydrolysis. The results suggested that when small peptides increased
51 by trypsin hydrolysis of the SPD1 ACE inhibitory capacity also increased up to 24 h, and
52 then decreased which may be due to disappearance of some active ingredients. Six
53 peptides, namely GFR, FK, IMVAEAR, GPCSR, CFCTKPC and MCESASSK, were
54 synthesized based on the simulated trypsin digest of SPD1, then tested for ACE inhibitory
55 activity. IC₅₀ values of individual peptides were 94.25 ± 0.32, 265.43 ± 1.24, 84.12 ± 0.53,
56 61.67 ± 0.36, 1.31 ± 0.07 and 75.93 ± 0.64 µM, respectively, suggesting that CFCTKPC
57 might represent the main domain for the ACE inhibition. SPD1 and its hydrolysates might
58 be good for hypertension and other disease control when people consume sweet potato
59 tuberous storage roots.

60

61 **Keywords:** Sweet Potato; Defensin; Angiotensin converting enzyme (ACE); Inhibition.

62

63 INTRODUCTION

64 Many bioactive peptides have common structural properties that include a relatively
65 short peptide residue length (e.g. 2 - 9 amino acids), possessing hydrophobic amino acid
66 residues in addition to proline, lysine or arginine groups (Lin et al., 2006). Bioactive
67 peptides are among the many functional components identified in foods. These are small
68 protein fragments that have biological effects once they are released during
69 gastrointestinal digestion in the organism or by previous *in vitro* protein hydrolysis.
70 Bioactive peptides with immunostimulating (Huang et al., 2010), antioxidant or
71 **angiotensin-converting enzyme (ACE)** inhibitor (Liu et al., 2007), antithrombotic
72 (Scarborough, 1991), bactericidal (Bellamy et al., 1993) functions were the research focus
73 in recent years.

74 ACE (peptidyl dipeptide hydrolase EC 3.4.15.1) is a glycoprotein and a
75 dipeptide-liberating exopeptidase classically associated with the renin-angiotensin system
76 regulating peripheral blood pressure (Mullally et al., 1996). ACE removes a dipeptide
77 from the C-terminus of angiotensin I to form angiotensin II, a very hypertensive
78 compound (Lin et al., 2008). Several endogenous peptides, such as enkephalins,
79 β -endorphin, and substance P, were reported to be competitive substrates and inhibitors of
80 ACE. Several food-derived peptides from α -lactoalbumin, β -lactoglobulin
81 (Pihlanto-Leppälä et al., 1998), mucilage (Huang et al., 2006) and trypsin inhibitor (TI)
82 (Huang et al., 2007) also inhibited ACE. Several antioxidant peptides (reduced
83 glutathione and carnosine-related peptides) (Hou et al., 2003) and synthetic peptides also
84 exhibited ACE inhibitor activities (Huang et al., 2006).

85 Plant defensins were originally termed γ -thionins because they have a similar size (5
86 kDa) and the same number of disulfide bridges (four) as α - and β -thionins. **γ -Thionins**
87 are structurally different from those of α - and β -thionins and instead rather similar to

88 insect and mammalian defensins structurally as well as functionally. Thus this class of
89 plant peptides was named ‘plant defensins’ (Haasen and Goring; 2010). A variety of plant
90 defensins have been isolated and characterized from many plant species including
91 monocots and dicots (Terras et al., 1992). Plant defensin families have been known as
92 potent growth inhibitors of a broad spectrum of fungi and bacteria, however the
93 antimicrobial activity of the plant defensins has been quite diverse and was classified into
94 two main groups (A and B) sharing only 25% similarity based on amino acid sequence
95 (Harrison, 1998). Plant defensins have been detected in different organs of plants such as
96 leaves, flowers, seeds, and tubers (Moreno et al., 1994). Furthermore, the expression of
97 some defensin genes is developmentally regulated, whereas that of others is greatly
98 elevated in response to biotic and abiotic external stimuli (Epple et al., 1997).

99 In our previous report, SPD1 exhibited antimicrobial, dehydroascorbate reductase
100 and monodehydroascorbate reductase activities (Huang et al., 2008a). In this work we
101 report for the first time that SPD1 exhibited dose-dependent ACE inhibitory activity when
102 Captopril was used as a positive control. Commercial bovine serum albumin (BSA),
103 which was frequently found in the literature as the peptide resource of ACE inhibitors,
104 was chosen for comparison. The K_i values of SPD1 against ACE were calculated. We also
105 used trypsin to hydrolyze SPD1 for different times, and the changes of ACE inhibitory
106 activity were determined. IC_{50} of ACE inhibitory activities by synthetic peptides were
107 also determined.

108

109 **MATERIALS and METHODS**

110 **Materials**

111 Tris, electrophoretic reagents, and silica gel 60 F254 were purchased from E. Merck
112 Inc. (Darmstadt, Germany); Captopril was purchased from Calbiochem Co. (CA, USA);
113 Seeblue prestained markers for SDS-PAGE including myosin (250 kDa), BSA (98 kDa),
114 glutamic dehydrogenase (64 kDa), alcohol dehydrogenase (50 kDa), carbonic anhydrase
115 (36 kDa), myoglobin (30 kDa), and lysozyme (16 kDa) were from Invitrogen (Groningen,
116 The Netherlands); FAPGG, ACE (1 unit, rabbit lung); Coomassie brilliant blue G-250;
117 peptide (GL Biochem, China), and other chemicals and reagents were purchased from
118 Sigma Chemical Co. (St. Louis, MO, USA).

119

120 **Expression of Defensin in *E. coli***

121 Defensin with its pre-pro-sequence (SPD1) was expressed in *E. coli*. The coding
122 sequence was amplified from cDNA SPD1 using an oligonucleotide (5'-A GGATCCATG
123 GCTTC ATCTC TTCGT TC -3'), with a *Bam*HI site (underlined) at the putative initial
124 Met residue, and an oligonucleotide (5'-GCCTT GCTAA TTCAG TCGAC CGCTG T
125 -3'), with a *Sal*I site at the 3' end. The PCR fragment was subcloned in pGEM T-easy
126 vector. The plasmid was then digested with *Bam*HI and *Sal*I and the excised fragments
127 were subcloned in pQE30 expression vector (QIAexpress expression system, Qiagen).
128 The resulting plasmid, termed pQE-SPD1, was introduced into *E. coli* (M15). Cultures of
129 the transformed *E. coli* (M15) overexpressed a protein of the expected molecular mass,
130 which was purified by affinity chromatography in Ni-nitrilotriacetic acid (NTA) columns
131 (Qiagen), according to Huang et al. (2004).

132

133 **Determination of ACE inhibitory activity**

134 The ACE inhibitory activity was measured according to the method of Holmquist et al.
135 (1979) with some modifications. Four microliters (4 microunits) of commercial ACE (1
136 unit, rabbit lung) was mixed with 50 μ L of different amounts of SPD1 or BSA (50, 100,

137 and 200 µg/mL), and then 200 µL of 0.5 mM *N*-[3-(2-furyl) acryloyl]-Phe-Gly-Gly
138 [FAPGG, dissolved in 50 mM Tris-HCl buffer (pH 7.5) containing 0.3 M NaCl] was
139 added. The decreased absorbance at 345 nm (ΔA inhibitor) was recorded during 5 min at
140 room temperature. Deionized water was used instead of sample solution for blank
141 experiments (ΔA control). Captopril (molecular mass 217.3 Da) was used as a positive
142 control for ACE inhibitor (1.25, 2.5, 5, 10, 20, 40 and 80 nM). The ACE activity was
143 expressed as ΔA 345 nm, and the ACE percent inhibition was calculated as follows: $[1 -$
144 $(\Delta A \text{ inhibitor} / \Delta A \text{ control})] \times 100$. Means of triplicates were determined. The 50%
145 inhibition (IC_{50}) of ACE activity was defined as the concentrations of samples that
146 inhibited 50% of ACE activity under experimental conditions.

147

148 **Determination of ACE inhibitory activity by TLC**

149 The ACE inhibitor activity of SPD1 was also determined by TLC method (Holmquist
150 et al., 1979). Each 100 µL of SPD1 or BSA (225 µg/mL) was premixed with 15
151 microunits of ACE for 1 min, and then 200 µL of 0.5 mM FAPGG was added and
152 allowed to react at room temperature for 10 min. Then 800 µL of methanol was added to
153 stop the reaction. The blank experiment contained FAPGG only; in the control experiment,
154 ACE reacted with FAPGG under the same conditions. Each was dried under reduced
155 pressure and redissolved with 400 µL of methanol, and 50 µL was spotted on a silica gel
156 60 F254. The FAPGG and FAP (ACE hydrolyzed product) were separated by TLC in
157 1-butanol-acetic acid-water, 4:1:1 (V/V/V), and observed under UV light.

158

159 **Determination of the kinetic properties of ACE inhibition by Defensin**

160 The kinetic properties of ACE (4 µU) without or with SPD1 (200 µg/mL) in a total
161 volume of 250 µL were determined using different concentrations of FAPGG as substrate
162 (0.1 mM to 0.5 mM). The K_m (without SPD1) and K_m' (with SPD1) were calculated

163 from Lineweaver-Burk plots, where K_m' was the Michaelis constant in the presence of
164 200 $\mu\text{g/mL}$ SPD1.

165

166 **Determination of the ACE Inhibitory Activity by trypsin Hydrolysates of Defensin**

167 Six mg of SPD1 were dissolved in 1 mL of 50 mM Tris-HCl buffer (pH 7.9). Then 0.1
168 mL of 12 mg of trypsin was added and hydrolysis was carried out at 37 °C for 8, 16, 24
169 and 32 h. After hydrolysis the solution was heated at 100 °C for 5 min to stop enzyme
170 reaction. The trypsin was heated before SPD1 hydrolysis for the 0 h control reaction. Each
171 of the 60 μL SPD1 hydrolysates was used for determinations of ACE inhibition by using
172 spectrophotometry.

173

174 **Chromatograms of Tryptic Hydrolysates of defensin on a Sephadex G-50 Column**

175 The unhydrolyzed SPD1 and tryptic SPD1 hydrolysates at 24 h were separated by
176 Sephadex G-50 chromatography (1 x 60 cm). The column was eluted with 20 mM
177 Tris-HCl buffer (pH 7.9). The flow rate was 30 mL/h, and each fraction contained 2 mL,
178 the absorbance of which was determined at 570 nm.

179

180 **Statistical Analysis**

181 Means of triplicates were calculated. Student's *t* test was used for comparison between
182 two treatments. A difference was considered to be statistically significant when $p < 0.05$.

183

184 RESULTS and DISCUSSION

185 **Expression of defensin in *E. coli***

186 SDS-PAGE analysis of SPD1 crude extracts from the transformed *E. coli* (M15)
187 showed high amounts of a polypeptide with the expected molecular mass (ca. 8,600 Da).
188 This polypeptide was found as a soluble protein in the supernatant, and was absent in
189 protein extracts obtained from *E. coli* transformed with pQE-30 vector. The expressed
190 protein was purified from crude extracts by Ni²⁺-chelate affinity chromatography, which
191 yielded highly purified His-tagged SPD1. Preparing SDS-PAGE (Huang et al., 2008a)
192 was used as the next step for SPD1 purification.

193

194 **Determination of ACE inhibitor Activity of Defensin by Spectrophotometry**

195 The purified SPD1 was used for determinations of ACE inhibitory activity. Fig. 1
196 shows time course of the effect of the different amounts of SPD1 (0, 50, 100 and 200
197 µg/mL) on the ACE activity (ΔA 345 nm). Compared with the ACE only (control), it was
198 found that the higher the amount of SPD1 added the lower the ΔA 345 nm found during
199 300 sec reaction period. Results of Fig. 1 shows that purified SPD1 could inhibit ACE
200 activity in a dose-dependent manner.

201

202 **Effects of Defensin, BSA and Captopril on ACE Activity shown by** 203 **Spectrophotometry**

204 It was interesting to know whether BSA also exhibited the ACE inhibitory activity.
205 Fig. 2A shows the effects of SPD1 (0, 50, 100, and 200 µg/mL), BSA (0, 50, 100, and 200
206 µg/mL) or Captopril (Fig. 2B; 0, 1.25, 2.5, 5, 10, 20, 40 and 80 nM; corresponding to 0,
207 108.5, 217, 434, 868, 1,736, 3,472 and 6,844 ng/mL, respectively) on ACE activity. It was
208 found that BSA showed less ACE inhibitory activity (less than 25 % inhibition) and

209 without dose-dependent inhibition patterns. However, SPD1 exhibited dose-dependent
210 ACE inhibitory activity (50~200 µg/mL giving, respectively, 27.56 ~ 52.58 % inhibition).
211 From calculations, the 50% inhibition (IC₅₀) of SPD1 against ACE activity was
212 190.47 µg/mL compared to that of 10 nM (868 ng/mL) for Captopril, which was similar
213 to the report (7 nM) of Pihlanto-Leppälä et al. (1998); while the IC₅₀ of yam dioscorin
214 was 250 µg/mL (Hsu et al., 2002). Both BSA and purified SPD1 were proteins, but only
215 the purified SPD1 showed specific dose-dependent ACE inhibitory activity. In the
216 literature, the protein hydrolysates were used as sources to purify peptides as ACE
217 inhibitors (Mullally et al., 1996). From calculations, the IC₅₀ of SPD1 against ACE
218 activity was 190.47 µg/mL, which was smaller than the synthetic peptide α-lactorphin
219 (YGLF, 322.7 µg/mL). Several identified peptide fragments exhibited much lower IC₅₀
220 values than our purified SPD1; for example, Tyr-Pro of whey proteins, 8.1 µg/mL
221 (Yamamoto et al., 1999) and HHL of soybean proteins, 2.2 µg/mL (Shin et al., 2001). On
222 the opposite, several identified peptide fragments exhibited much higher IC₅₀ values than
223 our purified SPD1; for example, hydrolysates of whey proteins (α-lactalbumin and
224 β-lactoglobulin) were effective with IC₅₀ values between 345-1,733 µg/mL
225 (Pihlanto-Leppälä et al., 2000), LAHKAL of α-lactalbumin hydrolysates, 406 µg/mL;
226 GLDIQK of β-lactoglobulin hydrolysates, 391 µg/mL; and VAGTWY of β-lactoglobulin
227 hydrolysates, 1,171 µg/mL. In our previous paper (Huang et al., 2008b), the IC₅₀ of ACE
228 activity required 187.96 µg/mL TI from sweet potato, which was lower than IC₅₀ value
229 of purified SPD1.

230

231 **Determinations of ACE Inhibitor Activity of Defensin by TLC**

232 The FAPGG and FAP (product of ACE catalyzed hydrolysis reaction) were separated
233 by TLC using water saturated 1-butanol: acetic acid: water, 4:1:1 (V/V/V) as developing
234 solvents according to the method of Holmquist et al. (1979). Fig. 3 shows the qualitative

235 results of TLC chromatograms of a silica gel 60 F254 about the effects of 225 $\mu\text{g}/\text{mL}$ of
236 commercial BSA (lane 3) or SPD1 (lane 4) on 15 microunits of ACE. Compared to the
237 control test (lane 2), it was found that SPD1 (lane 4) inhibited ACE reaction showing less
238 amounts of FAP production observed under UV light. However, similar amounts of FAP
239 were found between the control test (lane 2) and BSA (lane 3). These results
240 demonstrated again that SPD1 exhibited ACE inhibitor activity.

241

242 **Determination of the Kinetic Properties of ACE Inhibition by Defensin**

243 The Lineweaver-Burk plots of ACE (4 μU) without or with purified SPD1 (200 $\mu\text{g}/\text{mL}$)
244 under different concentrations of FAPGG are shown in Fig. 4. The results indicated that
245 purified SPD1 acted as a mixed type inhibitor against ACE using FAPGG as a substrate.
246 **When 200 $\mu\text{g}/\text{mL}$ SPD1 (10 μg) were added,** V_{max} and K_{m} were, respectively, 0.01
247 $\Delta\text{A}/\text{min}$ and 0.69 mM; while without SPD1 they were 0.03 $\Delta\text{A}/\text{min}$ and 0.42 mM. In
248 conclusion, SPD1 exhibited dose-dependent ACE inhibitory activity and acted as a mixed
249 type inhibitor with respect to the substrate (FAPGG). A similar work was reported with
250 the calculated K_{m} as 0.25 mM FAPGG for ACE in the presence of purified dioscorin, the
251 calculated K_{m}' was 0.33 mM (Hsu et al., 2002).

252 **The mixed-type inhibition suggests that there might be an inhibitor-binding site (or**
253 **I-site) for SPD1 on the enzyme (ACE) surface in addition to the substrate-binding site (or**
254 **S-site). It is noteworthy that SPD1 bind tighter to the I-site on the substrate-bound form of**

255 ACE than that on the free form. It is also noted that the K_m values in the presence of the
256 inhibitors are higher than that in their absence. In other words, binding of the substrate to
257 the S-site increases the binding affinity of the inhibitor to the I-site, whereas binding of
258 the inhibitor to the I-site decreases the binding affinity of the substrate to the S-site. The
259 inhibitory mode of SPD1 was unique and hardly analyzed with a simple
260 Michaelis–Menten-type interaction between the enzyme and inhibitor. The inhibitory
261 mode of SPD1 must be examined further in the next research step kinetically and
262 thermodynamically.

263

264 **Determination of the ACE Inhibitory Activity by trypsin Hydrolysates of Defensin**

265 **and their peptide Distributions.** Fig. 5 shows the ACE inhibitory activity (ΔA 345 nm)

266 of tryptic SPD1 hydrolysates. Fig. 5A shows the ACE inhibition (percent) of tryptic SPD1

267 hydrolysates collected at different trypsin hydrolysis times. From the results (Fig. 5A), it

268 was found that the ACE inhibitory activity increased from 52.47 % (0 h) to about 74.38 %

269 (24 h). Fig. 5B shows the chromatograms of unhydrolyzed SPD1 and tryptic SPD1

270 hydrolysates (24 h) on Sephadex G-50 column. It was found that smaller peptides

271 increased with increasing trypsin hydrolytic time. The ACE inhibitor activities of tryptic

272 SPD1 hydrolysates decreased after 24 h hydrolysis (Fig. 5A) suggesting that some active

273 ingredients got lost after 24 h hydrolysis.

274 We used synthetic peptides (according to SPD1 gene sequence) to measure ACE
275 inhibitor activity. Kohmura et al. (1989) synthesized some peptide fragments of human
276 β -casein and found that the length of those peptides had an influence on the ACE
277 inhibitory activity. Namely, peptides composed of 3-10 amino acids with proline on the
278 C-terminal were necessary as ACE inhibitors. Thus the peptide Leu-Arg-Pro from food
279 protein hydrolysates has been reported to be the most potent natural ACE inhibitor, with
280 an IC_{50} value of $0.27 \mu\text{g/mL}$ or $1.0 \mu\text{M}$. Byun and Kim (2002) studied the ACE inhibitory
281 activity of a series of dipeptides, and indicated that tryptophan, tyrosine, proline, or
282 phenylalanine at the C-terminal and branched-chain aliphatic amino acid at the N-terminal
283 were required for a peptide to bind to ACE.

284 Synthetic peptides were designed by simulated trypsin cutting sites of *SPD1* gene
285 (accession number: AY552546) products from sweet potato
286 (<http://www.expasy.org/tools/peptidecutter/>). Six peptides, namely GFR, FK, IMVAEAR,
287 GPCSR, CFCTKPC and MCESASSK, were synthesized based on the simulated trypsin
288 digest of SPD1, then tested for ACE inhibitory activity. IC_{50} values of individual peptides
289 were 94.25 ± 0.32 , 265.43 ± 1.24 , 84.12 ± 0.53 , 61.67 ± 0.36 , 1.31 ± 0.07 and 75.93 ± 0.64
290 μM , suggesting that CFCTKPC might represent the main domain for the ACE inhibition.
291 These results demonstrated that simulated synthetic peptides from tryptic SPD1
292 hydrolysates exhibited ACE inhibitory activities. Our work suggests that (1) CFCTKPC
293 might represent the main active site for the ACE inhibition; (2) there are marked structural
294 similarities for peptides with antihypertensive, immunomodulatory and antioxidant
295 activities and may be used as criteria for selecting or designing multifunctional
296 ingredients of functional foods to control cardiovascular diseases.

297 In our previously paper, TI was shown to inhibit ACE activation in a
298 dose-dependent manner. The IC_{50} of ACE activity required $187.96 \mu\text{g/mL}$ TI. And
299 TYCQ was synthesized based on the simulated pepsin digest of TI. The IC_{50} values of

300 TYCQ peptide was 2.30 μM (Huang et al., 2008b). In this work the IC_{50} values of
301 CFCTKPC peptide was 1.31 μM . This value was much better than TI and its hydrolysates.
302 CFCTKPC peptide contains seven amino acids with three cysteine residues. So far, the
303 structure–activity correlations among the various ACE inhibitory peptides still remain
304 ambiguous. On the basis of some common structure patterns, it has been suggested that
305 the most favorable amino-terminal residues are branched amino acids such as Val and Ile
306 and the most preferred carboxyterminus residues are among Trp, Tyr, Pro, or Phe (Zhou et
307 al., 2010).

308 In summary, SPD1 exhibited dose-dependent ACE inhibitory activity. SPD1 acted as
309 a mixed type inhibitor toward ACE with IC_{50} of $1.31 \pm 0.07 \mu\text{M}$. Its peptic hydrolysates
310 also showed ACE inhibitory activities. Some peptides derived from food proteins were
311 demonstrated to have antihypertensive activities against spontaneously hypertensive rats
312 (Yoshii, et al., 2001). The potential for hypertension control when people consume sweet
313 potato deserves further investigations.

314

315 **ACKNOWLEDGEMENTS**

316 The authors want to thank the financial supports from the National Science Council
317 (NSC 97-2313-B-039 -001 -MY3) and China Medical University (CMU) (CMU95-PH-11,
318 CMU96-113, CMU97-232 and CMU99-S-29).

319

320 **LITERATURE CITED**

321 Bellamy, W., R.H. Wakabayashi, M. Takase, K. Kawase, S. Shimamura, and M. Tomita.
322 1993. Role of cell-binding in the antibacterial mechanism of Lactoferricin B. *J. Appl.*
323 *Bacteriol.* **75**: 478-484.

324 Byun, H.G., and S.K. Kim. 2002. Structure and activity of angiotensin I converting
325 enzyme inhibitory peptides derived from Alaskan pollack skin. *J. Biochem. Mol.*
326 *Biol.* **35**: 239-243.

327 Casaretto, H.Z., and P. Jolles. 1984. Immunostimulating hexapeptide from human case in
328 amino acid sequence, synthesis and biological properties. *Eur. J. Biochem.* **145**:
329 677-682.

330 Haasen, K.E., and D.R. Goring. 2010. The recognition and rejection of self-incompatible
331 pollen in the *Brassicaceae*. *Botanical Studies.* **51**: 1-6.

332 Epple, P., K. Apel, and H. Bohlmann. 1997. ESTs reveal a multigene family for plant
333 defensins in *Arabidopsis thaliana*. *FEBS Lett.* **400**: 168-172.

334 Harrison, P.F. and J. Lederberg. 1998. Antimicrobial Resistance. National Academies
335 Press.

336 Holmquist, B., P. Bunning, and J.F. Riordan. 1979. A continuous spectrophotometric
337 assay for angiotensin converting enzyme. *Anal. Biochem.* **95**: 540-548.

338 Hou, W.C., H.J. Chen, and Y.H. Lin. 2003. Antioxidant peptides with angiotensin
339 converting enzyme inhibitory activities and applications for angiotensin converting
340 enzyme purification. *J Agric Food Chem.* **51**: 1706-1709.

341 Hsu, F.L., Y.H. Lin, M.H. Lee, C.L. Lin, and W.C. Hou. 2002. Both dioscorin, the tuber
342 storage protein of yam (*Dioscorea alata* cv. Tainong No. 1), and its peptic
343 hydrolysates exhibited angiotensin converting enzyme inhibitory activities. *J Agric*
344 *Food Chem.* **50**: 6109-6013.

345 Huang, D.J., C.D. Lin, H.J. Chen, and Y.H. Lin. 2004. Antioxidant and antiproliferative
346 activities of sweet potato (*Ipomoea batatas* [L.] Lam. 'Tainong 57') constituents.
347 *Bot. Bull. Acad. Sin.* **45**: 179-186.

348 Huang, D.J., W.C. Hou, H.J. Chen, and Y.H. Lin. 2006. Sweet potato (*Ipomoea batatas*
349 [L.] Lam 'Tainong 57') storage roots mucilage exhibited angiotensin converting
350 enzyme inhibitory activities *in vitro*. *Botanical Studies.* **45**: 397-402.

351 Huang, G.J., H.J. Chen, Y.S. Chang, M.J. Sheu, and Y.H. Lin. 2007. Recombinant
352 Sporamin and its synthesized peptides with Antioxidant Activities *in vitro*. *Botanical*
353 *Studies.* **48**: 133-140.

354 Huang, G.J., H.C. Lai, Y.S. Chang, M.J. Sheu, T.L. Lu, S.S. Huang, and Y.H. Lin. 2008a.
355 Antimicrobial, dehydroascorbate reductase and monodehydroascorbate reductase
356 activities of defensin from sweet potato (*Ipomoea batatas* [L.] Lam. 'Tainong 57')
357 storage roots. *Journal of Agricultural and Food Chemistry* **56**: 2989-2995.

358 Huang, G.J., Y.L. Ho, H.J. Chen, Y.S. Chang, S.S. Huang, H.J. Hung, and Y.H. Lin.
359 2008b. Sweet potato storage root trypsin inhibitor and their peptichydrolysates
360 exhibited angiotensin converting enzyme inhibitory activity *in vitro*. *Botanical*
361 *Studies.* **49**: 101-108.

- 362 Huang, C.Y., C.L. Wen, Y.L. Lu, Y.S. Lin, L.G. Chen, and W.C., Hou. 2010.
363 Antihypertensive activities of extracts from tissue cultures of *Vitis thunbergii* var.
364 *Taiwaniana*. **Botanical Studies**. **51**: 317-325.
- 365 Kohmura, M., N. Nio, K. Kubo, Y. Minoshima, E. Munekata, and Y. Ariyoshi. 1989.
366 Inhibition of angiotensin-converting enzyme by synthetic peptide fragments of
367 human β -casein. *Agric. Biol. Chem.* **53**: 2107-2114.
- 368 Lin, C.L., S.Y. Lin, Y.H. Lin, and W.C. Hou. 2006. Effects of tuber storage protein of yam
369 (*Dioscorea alata* cv. Tainong No. 1) and its peptic hydrolyzates on spontaneously
370 hypertensive rats. *J. Sci. Food Agric.* **86**: 1489-1494.
- 371 Lin, S.Y., C.C. Wang, Y.L. Lu, W.C. Wu, and W.C. Hou. 2008. Antioxidant,
372 anti-semicarbazide-sensitive amine oxidase, and antihypertensive activities of
373 geraniin isolated from *Phyllanthus urinaria*. *Food Chem. Toxicol.* **46**: 2485-2492.
- 374 Liu, Y.H., M.T. Chuang, and W.C. Hou. 2007. Methanol-soluble, β -elimination products
375 from preparations of alginic acid hydroxamate exhibited DPPH scavenging and
376 angiotensin converting enzyme inhibitory activities. **Botanical Studies**. **48**: 141-146.
- 377 Moreno, M., A. Segura, and F. Garcia-Olmedo. 1994. Pseudothionin-St1, a potato peptide
378 active against potato pathogens. *Eur. J. Biochem.* **223**: 135-139.
- 379 Mullally, M.M., H. Meisel, and R.J. Fitzgerald. 1996. Synthetic peptides corresponding to
380 α -lactalbumin and β -lactoglobulin sequences with angiotensin-I-converting enzyme
381 inhibitory activity. *J. Biol. Chem.* **377**: 259-260.

382 Pihlanto-Leppälä, A., T. Rokka, and H. Korhonen. 1998. Angiotensin I converting
383 enzyme inhibitory peptides derived from bovine milk proteins. *Int. Dairy J.* **8**:
384 325-331.

385 Pihlanto-Leppälä, A., P. Koskinen, K. Piilola, T. Tupasela, and H. Korhonen. 2000.
386 Angiotensin I-converting enzyme inhibitory properties of whey protein digest:
387 concentration and characterization of active peptides. *J. Dairy Sci.* **67**: 53-64.

388 Scarborough, R.H., J.W. Rose, M.H. Hsu, D.R. Phillips, V.A. Fried, A.M. Campbell, L.
389 Manniaai, and I.F. Charo. 1991. Barbourin A GpIIb-IIIa specific integrin antagonist
390 from the venom of sistrurus *M. barbouri*. *J. Biol. Chem.* **266**: 9359- 9360.

391 Shin, Z.I., R. Yu, S.A. Park, D.K. Chung, C.W. Ahn, H.S. Nam, K.S. Kim, and H.J. Lee.
392 2001. His-His-Leu, an angiotensin I converting enzyme inhibitory peptide derived
393 from Korean soybean paste, exerts antihypertensive activity *in vivo*. *J. Agric. Food*
394 *Chem.* **49**: 3004-3009.

395 Terras, F.R., I.J. Goderis, F. Van Leuven, J. Vanderleyden, B.P. Cammue, and W.F.
396 Broekaert. 1992. *In Vitro* Antifungal Activity of a Radish (*Raphanus sativus* L.)
397 Seed Protein Homologous to Nonspecific Lipid Transfer Proteins. *Plant Physiol.*
398 **100**: 1055-1058.

399 Yamamoto, N., M. Maeno, and T. Takano. 1999. Purification and characterization of an
400 antihypertensive peptide from a yogurt-like product fermented by *Lactobacillus*
401 *helveticus* CPN4. *J. Dairy Sci.* **82**: 1388-1393.

402 Yoshii, H., N. Tachi, R. Ohba, O. Sakamura, H. Takeyama, and T. Itani, 2001.
403 Antihypertensive effect of ACE inhibitory oligopeptides from chicken egg yolks.

404 Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol. **128**: 27-33.

405 Zhou, F., Z. Xue, and J. Wang, 2010. Antihypertensive effects of silk fibroin hydrolysate

406 by alcalase and purification of an ACE inhibitory dipeptide. J Agric Food Chem. **58**:

407 6735-6740.

408

409

410

411 **Figure Legends**

412 Figure 1. Inhibitory activity of different amounts of defensin (SPD1) (0, 50, 100 and 200
413 $\mu\text{g}/\text{mL}$) from sweet potato storage root on the ACE activity (ΔA 345 nm).

414

415 Figure 2. The effects of SPD1, albumin and Captopril on ACE activity determined by
416 spectrophotometry. SPD1 (0, 50, 100 and 200 $\mu\text{g}/\text{mL}$) or bovine serum
417 albumin (0, 50, 100 and 200 $\mu\text{g}/\text{mL}$) was used. The inhibition of ACE (%)
418 was calculated according to the equation $[1 - (\Delta A \text{ inhibitor} \div \Delta A \text{ control})] \times$
419 100 %.

420

421 Figure 3. The TLC chromatograms of a silica gel 60 F254 showing the effects of defensin
422 from sweet potato storage root or bovine serum albumin on ACE activity.
423 Lane 1, blank test (FAPGG only); lane 2, control test (ACE reacted with
424 FAPGG to produce FAP); lane 3, 225 $\mu\text{g}/\text{mL}$ bovine serum albumin added;
425 lane 4, 225 $\mu\text{g}/\text{mL}$ SPD1 added. Each solution was dried under reduced
426 pressure and redissolved with 400 μL methanol. Each 50 μL was spotted on a
427 silica gel 60 F254. The FAPGG and FAP were separated by water saturated
428 1-butanol : acetic acid : water, 4:1:1 (V/V/V). Arrows indicated the positions
429 of both FAP and FAPGG.

430

431 Figure 4. The Lineweaver-Burk plots of ACE (4 μ U) without or with SPD1 (200 μ g/mL)
432 from sweet potato storage root using different concentrations of FAPGG (0.1
433 to 0.5 mM).


434

435 Figure 5. ACE inhibitor activity of tryptic hydrolysates of sweet potato SPD1. The plot
436 shows the ACE inhibition (%) of tryptic SPD1 hydrolysates obtained at
437 different trypsin hydrolysis time (A). The proteins and the inhibition of ACE
438 (%) were shown (B). The inhibition of ACE (%) was calculated according to
439 the equation $[1 - (\Delta A \text{ inhibitor} \div \Delta A \text{ control})] \times 100 \%$.

440

441

442 **Figure 1.**



443

444


445

446

447 **Figure 2.**


448

449 **A.**



450

451 **B.**




452

453

454

455 **Figure 3.**

456



457


458

459

460

461 **Figure 4.**

462



463

464


465

466

467


468 **Figure 5.**

469 **A.**



470

471 **B.**



472

473

474

475

476 **Table 1.** SPD1 peptides with ACE inhibition activity.

477

SPD1 peptides	IC ₅₀ (μM)
GFR	94.25 ± 0.32
FK	265.43 ± 1.24
IMVAEAR	84.12 ± 0.53
GPCSR	61.67 ± 0.36
CFCTKPC	1.31 ± 0.07
MCESASSK	75.93 ± 0.64

478 Note: The sequence of SPD1 contains pre-pro-sequence. These sequences were retrieved

479 from the NCBI (National Center for Biotechnology Information,

480 <http://www.ncbi.nlm.nih.gov>) with the following accession numbers AY552546.

481

482

483

484

485

486

487

488 甘藷塊根中防禦素及其合成之胜肽具有血管收縮素轉化酶抑制活性

489 黃冠中¹ 陸德齡² 邱傳淞^{1,3} 陳顯榮⁴ 吳介信² 林穎志⁵ 謝文聰⁶ 廖容君² 許明志² 林耀輝⁷

490 ¹ 中國醫藥大學中國藥學暨中藥資源系

491 ² 中國醫藥大學藥學系

492 ³ 新生醫護管理專科學校護理科

493 ⁴ 中山大學生命科學系

494 ⁵ 仁德醫護管理專科學校護理科

495 ⁶ 中國醫藥大學醫學系藥理學科

496 ⁷ 中央研究院植物暨微生物研究所

497

498 在大腸桿菌(M15)中大量表現甘藷塊根之重組蛋白質防禦素(SPD1)，利用鎳離子
499 螯合之親和性管柱純化。SPD1 經 SDS-PAGE 分析其分子量約為 8,600 Da. 由以前的
500 研究發現 SPD1 具有抗微生物活性，去氫抗壞血酸還原酶，單去氫抗壞血酸還原酶的
501 活性。SPD1 以 *N*-[3-(2-furyl) acryloyl]-Phe-Gly-Gly (FAPGG)為受質，利用分光光度
502 計的方法分析抑制血管收縮素轉化酶 (angiotensin converting enzyme, ACE) 的
503 能力，其效果隨劑量增加而增加 (50 到 200 µg/mL SPD1，分別抑制 27.56 ~ 52.58%
504 血管收縮素轉化酶活性)。SPD1 對於血管收縮素轉化酶之 50% 抑制濃度 (IC₅₀) 為
505 190.47 µg/mL，對照組 Captopril 為 10 nM (868 ng/mL)。另外利用螢光 silica TLC
506 偵測 FAPGG 及其水解產物 FAP，結果也顯示 SPD1 對於血管收縮素轉化酶有抑制的
507 效果。SPD1 對於血管收縮素轉化酶是屬於混合型抑制。利用胰蛋白酶以不同時間水
508 解 SPD1 時，發現反應 24 小時時其血管收縮素轉化酶活性有抑制的效果可以從 52.47
509 % (0 h) 增加到 74.38 % (24 h)。由結果可知小分子的胜肽會隨著水解時間增加且
510 血管收縮素轉化酶活性抑制也有增加，但水解時間超過 24 h 時，血管收縮素轉化酶
511 活性抑制會降低，可能是由於一些胜肽的結構被破壞。利用電腦模擬胰蛋白酶水解
512 SPD1 的結果，得到六種人工合成具有抑制血管收縮素轉化酶活性胜肽：GFR, FK,
513 IMVAEAR, GPCSR, CFCTKPC 和 MCESASSK，測定其 IC₅₀ 為 94.25±0.32, 265.43±
514 1.24, 84.12±0.53, 61.67±0.36, 1.31±0.07 和 75.93±0.64 µM。結果發現 CFCTKPC
515 具有很好的抑制血管收縮素轉化酶活性。當人們食用甘藷塊根時，SPD1 及其胜肽也
516 許對於高血壓和其他疾病的控制是有益的。

517 關鍵詞：甘藷；防禦素；血管收縮素轉化酶；抑制作用。